Based in Aachen, Germany, the company's ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and increase annual revenues to two billion euros. It has a strong presence in Europe and Latin America, and chief executive Gabriel Baertschi is seeking to grow the business from a geographic footprint point of view.